Suzy Ghazarian

Phase I trial of lorlatinib in patients with ALK-driven refractory or relapsed neuroblastoma: A New Approaches to Neuroblastoma Consortium study.

S. Groshen, J. Maris, K. Matthay, 2020 .

Circulating tumor DNA reveals mechanisms of lorlatinib resistance in patients with relapsed/refractory ALK-driven neuroblastoma

J. Maris, Y. Mossé, M. Lemmon, 2023, Nature communications.

Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results

S. Groshen, J. Maris, K. Matthay, 2023, Nature Medicine.